Back to results

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

Objective

To evaluate recurrence-free survival (RFS) in participants with resected pancreatic neuroendocrine tumors (pNETs) randomized to treatment with capecitabine + temozolomide (CAPTEM) compared to observation only.

Protocol #

S2104

Trial Phase:

Phase II

Principal Investigator:

Myers, Jennifer

Cancer Type
  • Other Endocrine System
  • Pancreas
Study Site
  • Stony Point
  • Virginia Commonwealth University

Participants must have a histologic diagnosis of well-differentiated pancreatic neuroendocrine tumor (pNET) that was resected between 14 and 90 days prior to registration.
Resection must have been an R0 or R1 per treating investigator's assessment and/or pathology report.
Participants may have received resection/ablation of liver oligo-metastatic disease (up to 5 liver metastases) at the time of well-differentiated pNET resection
Participants must not have unresected or unablated metastatic disease.
Participants must not have clinically apparent central nervous system metastases or carcinomatous meningitis.
Participants must be >/= 18 years old

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Carrie Donovan, RN
    Phone: +1 804-628-3836
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: